ALNYLAM PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Other Comprehensive Income (Loss), before Reclassifications, Net of Tax of $8.35 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax · last filed 2023-11-02
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2023-09-30 was $2.87M, a 522.08% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2023-06-30 was $4.07M.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2023-03-31 was $1.40M, a 41.06% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2022-12-31 was -$5.65M, a 289.08% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2022 was -$5.26M, a 142.80% decline from fiscal 2021.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2021 was $12.30M.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2020 was -$7.63M.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2019 was -$3.98M.
| Period end | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 3 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 6 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 9 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month |
|---|---|---|---|---|
| 2023-09-30 | $2.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $6.95M derived: sum of 2 quarters · filed 2023-11-02 | $8.35M 10-Q · filed 2023-11-02 | $2.70M derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | $4.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $5.47M 10-Q · filed 2023-08-03 | -$174.00K derived: sum of 3 quarters · filed 2023-08-03 | $288.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-03-31 | $1.40M 10-Q · filed 2023-05-04 | -$4.25M derived: sum of 2 quarters · filed 2023-05-04 | -$3.78M derived: sum of 3 quarters · filed 2023-11-02 | -$6.24M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-12-31 | -$5.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$5.18M derived: sum of 2 quarters · filed 2023-11-02 | -$7.64M derived: sum of 3 quarters · filed 2023-11-02 | -$5.26M 10-K · filed 2023-02-23 |
| 2022-09-30 | $462.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$1.99M derived: sum of 2 quarters · filed 2023-11-02 | $383.00K 10-Q · filed 2023-11-02 | $3.37M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$2.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$79.00K 10-Q · filed 2023-08-03 | $2.91M derived: sum of 3 quarters · filed 2023-08-03 | $4.54M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $2.38M 10-Q · filed 2023-05-04 | $5.36M derived: sum of 2 quarters · filed 2023-05-04 | $7.00M derived: sum of 3 quarters · filed 2023-05-04 | $7.83M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $4.62M derived: sum of 2 quarters · filed 2023-02-23 | $5.45M derived: sum of 3 quarters · filed 2023-02-23 | $12.30M 10-K · filed 2023-02-23 |
| 2021-09-30 | $1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $2.46M derived: sum of 2 quarters · filed 2022-10-27 | $9.31M 10-Q · filed 2022-10-27 | $3.34M derived: sum of 4 quarters · filed 2022-10-27 |
| 2021-06-30 | $827.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-28 | $7.67M 10-Q · filed 2022-07-28 | $1.71M derived: sum of 3 quarters · filed 2022-07-28 | -$3.00M derived: sum of 4 quarters · filed 2022-07-28 |
| 2021-03-31 | $6.85M 10-Q · filed 2022-04-28 | $879.00K derived: sum of 2 quarters · filed 2022-04-28 | -$3.83M derived: sum of 3 quarters · filed 2022-04-28 | -$2.44M derived: sum of 4 quarters · filed 2022-04-28 |
| 2020-12-31 | -$5.97M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | -$10.68M derived: sum of 2 quarters · filed 2022-02-10 | -$9.28M derived: sum of 3 quarters · filed 2022-02-10 | -$7.63M 10-K · filed 2022-02-10 |
| 2020-09-30 | -$4.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | -$3.31M derived: sum of 2 quarters · filed 2021-10-28 | -$1.66M 10-Q · filed 2021-10-28 | -$4.00M derived: sum of 4 quarters · filed 2021-10-28 |
| 2020-06-30 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $3.05M 10-Q · filed 2021-08-03 | $709.00K derived: sum of 3 quarters · filed 2021-08-03 | $2.03M derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $1.66M 10-Q · filed 2021-04-29 | -$683.00K derived: sum of 2 quarters · filed 2021-04-29 | $637.00K derived: sum of 3 quarters · filed 2021-04-29 | -$2.67M derived: sum of 4 quarters · filed 2021-04-29 |
| 2019-12-31 | -$2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$1.02M derived: sum of 2 quarters · filed 2021-02-11 | -$4.33M derived: sum of 3 quarters · filed 2021-02-11 | -$3.98M 10-K · filed 2021-02-11 |
| 2019-09-30 | $1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$1.99M derived: sum of 2 quarters · filed 2020-11-05 | -$1.64M 10-Q · filed 2020-11-05 | -$1.46M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | -$3.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$2.96M 10-Q · filed 2020-08-06 | -$2.78M derived: sum of 3 quarters · filed 2020-08-06 | -$3.44M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $346.00K 10-Q · filed 2020-05-06 | $525.00K derived: sum of 2 quarters · filed 2020-05-06 | -$134.00K derived: sum of 3 quarters · filed 2020-05-06 | |
| 2018-12-31 | $179.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | -$480.00K derived: sum of 2 quarters · filed 2020-02-13 | -$411.00K 10-K · filed 2020-02-13 | |
| 2018-09-30 | -$659.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | -$590.00K 10-Q · filed 2019-10-31 | ||
| 2018-06-30 | $69.00K 10-Q · filed 2019-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |